Editorially independent content, supported with advertising
06.09.22
Could an 8-mg dose intensify the therapeutic effect of aflibercept (Eylea, Regeneron) in patients with wet AMD? The phase 2 CANDELA study sought to explore the safety and efficacy of high-dose aflibercept in this patient population. What did David Brown, MD, and his research colleagues observe? And 96-week data from ARCHWAY are in. Did the complete study, which reached its primary endpoint after 40 weeks, reveal new data that could affect clinical decision-making when it comes to real-world use of the Port Delivery System with Ranibizumab (Susvimo, Genentech)? Hear our interview with Robert Mittra, MD, to find out. This editorially independent podcast is supported with advertising.
08.21.25
ASRS '25: PORTAL 5-year Data in Wet AMD, and Home OCT vs Human GradersJohn Kitchens, MD; Krishna Mukkamala, MD
06.12.25
Duke AVS Clips: PVR, DR, Imaging, and MTMJason Hsu, MD; Majda Hadziahmetovic, MD; Aleksandra Rachitskaya, MD; Gavin Tan, MD, PhD, FRCSed
06.09.25
Duke AVS Clips: Pediatrics, Anesthesia Trends, and AILejla Vajzovic, MD; Jason Fan, MD; Glen J. Jaffe, MD
06.05.25
Duke AVS Clips: Gene Therapy, RDs, IOLs, and PVDsAvni P. Finn, MD, MBA; Lejla Vajzovic, MD, MBA; David Zacks, MD, PhD; Dilraj S. Grewal, MD; Xi Chen, MD, PhD; Yuxi Zheng, MD; Durga Borkar, MD; and Yannek I. Leiderman, MD, PhD
05.29.25
ARVO '25: ISTH0036 in Wet AMD/DME, and New Photobiomodulation DataMarion Munk, MD, PhD; and Diana Do, MD
05.22.25
ARVO '25: Real-World Next-Gen Anti-VEGF Dosing and TKIs in the PipelineDavid Miller, MD; and Robert Wang, MD
12.05.24
AAO '24: Real-world PDR Treatment vs. Protocol S Guidelines, and Retinal Imaging for Alzheimer'sAdrienne Scott, MD; and Dilraj Grewal, MD
11.14.24
AAO '24 Late-Breakers: Preventing Fas Activation Prior to RRD Repair, and Phase 2/3 Data on an Oral Therapy for GADurga S. Borkar, MD, MMCi; and Alex Melamud, MD
11.07.24
AAO '24 Late-Breakers: ELEVATUM Study and Home OCT in Wet AMDJeremiah Brown, MD, MS; and Eric Schneider, MD
10.31.24
AAO '24: COVID and Retinal Disease, Plus the Latest on Step Therapy and Declining ReimbursementRahul Khurana, MD; and Paul Hahn, MD, PhD
Show More